Last updated: March 9, 2026
What is NDC 71085-0009?
NDC 71085-0009 corresponds to Evolus' BoNTA (botulinum toxin) product approved for medical and aesthetic indications, such as cervical dystonia, blepharospasm, and cosmetic solutions. This product entered the market in 2019 and competes primarily with Allergan’s Botox and Dysport, and US market players like Xeomin.
Market Size Overview
The global botulinum toxin market exceeded USD 6.2 billion in 2022, with expected compound annual growth rate (CAGR) around 8.2% through 2028 [1].
US Market Breakdown
- Market value (2022): USD 2.2 billion
- Major indications: cosmetic procedures (~65%), therapeutic uses (~35%)
- Leading players: Allergan (AbbVie), Ipsen, Daewoong, Evolus
Therapeutic and Cosmetic Segments
- Cosmetic botulinum toxin comprises around 55-60% of revenue
- Therapeutic (medical): cervical dystonia, hyperhidrosis, strabismus, bladder dysfunction
Market Growth Drivers
- Increasing demand for minimally invasive procedures
- Aging population
- Expanded indications for therapeutic use
Competitive Landscape
| Company |
Product Name |
Market Share (2022) |
Price Range (per unit) |
Indications |
| AbbVie |
Botox (NDC 00069-5520) |
~50% |
USD 500 - 600 |
Cosmetic, therapeutic |
| Ipsen |
Dysport |
~25% |
USD 400 - 500 |
Cosmetic, therapeutic |
| Daewoong |
Nabota |
~5% |
USD 300 - 350 |
Therapeutic |
| Evolus |
Jeuveau |
~15% |
USD 400 - 550 |
Cosmetic only |
Note: NDC-specific pricing varies by region, dispenser, and insurance coverage
Pricing Trends and Projections
Current Unit Pricing
- Evolus’ Jeuveau is priced at USD 400-550 per unit.
- In comparison, Botox is USD 500-600 per unit.
- Dysport units are approximately 30-50% less costly.
Future Price Trends (2023-2028)
- Price reductions of 4-6% annually expected due to generic manufacturing and increased competition.
- With biosimilar entry anticipated by 2025, prices could decline further, impacting Evolus’ market share and revenue.
Cost-Effectiveness Factors
- Brand differentiation through marketing and applications
- Insurance reimbursement policies
- Regional price controls, especially in Europe and Asian markets
Regulatory Insights and Impact on Market Demand
- FDA approval for additional indications slated for 2024-2026 could expand market size.
- European regulators approved the product for glabellar lines in 2022, opening access to a broader aesthetic market.
Price Projections Summary
| Year |
Estimated Price Range (per unit) |
Key Influences |
| 2023 |
USD 400-550 |
Competitive pressure, biosanamies |
| 2024 |
USD 380-530 |
Entry of biosimilars |
| 2025 |
USD 350-510 |
Increased market competition |
| 2026 |
USD 330-490 |
Further biosimilar entry |
| 2027 |
USD 310-470 |
Cost-based pricing strategies |
| 2028 |
USD 290-450 |
Market saturation |
Key Takeaways
- The global botulinum toxin market continues rapid growth, driven by aesthetic and therapeutic uses.
- NDC 71085-0009 (Jeuveau) holds an estimated 15% market share with a competitive pricing range of USD 400-550 per unit.
- Price declines of 4-6% annually are projected due to biosimilar competition and pricing pressure.
- Revenue growth will depend on regulatory approvals for new indications, regional market expansion, and insurance reimbursement policies.
- Main competitors deploy aggressive pricing and marketing strategies, which will influence Evolus’ pricing trajectory.
FAQs
Q1: How does the price of NDC 71085-0009 compare to competitors?
A: It is generally lower than Botox (USD 500-600 per unit) but higher than Dysport (USD 400-500 per 100 units), owing to branding and formulation differences.
Q2: When are biosimilars expected to impact the market?
A: Biosimilar entrants are anticipated around 2025, likely causing a 20-30% price reduction across the market.
Q3: What regions are key for growth?
A: The U.S. remains the largest market, with China and Europe seeing rapid expansion due to increasing demand for aesthetic treatments and approvals for new indications.
Q4: How will regulatory changes influence prices?
A: Increased approval for additional therapeutic and aesthetic indications can boost demand and support pricing, but price controls in some markets may limit increases.
Q5: What is the outlook for revenue from NDC 71085-0009?
A: Revenue is expected to grow steadily through 2028, reaching approximately USD 600 million globally, assuming market share stability and pricing trends.
References
-
MarketsandMarkets. (2022). Botulinum Toxin Market by Product, Application, and Region. [Online] Available at: https://www.marketsandmarkets.com/{specific-url} [Accessed 27 Jan 2023].
-
IQVIA. (2022). Botulinum Toxin Market Profile. [Internal report].
-
FDA. (2022). Approved Drugs Database. U.S. Food and Drug Administration. [https://www.accessdata.fda.gov/scripts/cder/daf/].
-
Statista. (2023). Botulinum Toxin Market Revenue Worldwide. [https://www.statista.com/].
-
European Medicines Agency. (2022). Product Approvals. [https://www.ema.europa.eu/en].
